Latest On Moderna, Inc (MRNA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-30 17:55 EST | News | Moderna, Merck post detailed Phase 2 data for mRNA cancer shot in melanoma | N/A |  |
| 2023-05-30 17:41 EST | News | Next set of COVID boosters to target new Omicron variants – WSJ | N/A | |
| 2023-05-26 13:54 EST | News | Moderna registers biotech unit in China with $100M investment | N/A | |
| 2023-05-24 19:31 EST | News | Moderna: Don't Try To Catch The Falling Knives | N/A | |
| 2023-05-24 05:06 EST | News | Why did Moderna stock jump today? Renewed COVID fears | N/A | |
About Moderna, Inc (MRNA):
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research read more... Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., and Recipharm for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
General
- Name Moderna, Inc
- Symbol MRNA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 1,300
- Fiscal Year EndDecember
- IPO Date2018-12-07
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.modernatx.com
Valuation
- Forward PE 15.87
- Price/Sales (Trailing 12 Mt.) 65.02
- Price/Book (Most Recent Quarter) 21.42
- Enterprise Value Revenue 62.82
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $21.85
- Next Year EPS Estimate $14.87
- Next Quarter EPS Estimate $1.67
- Profit Margin -93%
- Operating Margin -95%
- Return on Assets -11%
- Return on Equity -40%
- Revenue 803.4 million
- Earnings Per Share -$2.35
- Revenue Per Share $2.11
- Gross Profit -574877000
- Quarterly Earnings Growth 3960.8%
Highlights
- Market Capitalization 58.1 billion
- EBITDA -495969984
- PE Ratio -5.07
- Analyst Target Price $174.25
- Book Value Per Share $6.42
Share Statistics
- Shares Outstanding 400.52 million
- Shares Float 336.37 million
- % Held by Insiders 1001%
- % Held by Institutions 52.06%
- Shares Short 13.29 million
- Shares Short Prior Month 14.69 million
- Short Ratio 1.05
- Short % of Float 4%
- Short % of Shares Outstanding 3%
Technicals
- Beta 1.47
- 52 Week High $189.26
- 52 Week Low $24.36
- 50 Day Moving Average 157.08
- 200 Day Moving Average 112.5
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Moderna, Inc (MRNA) Dividend Calendar:
Moderna, Inc (MRNA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Moderna, Inc (MRNA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Moderna, Inc (MRNA) Chart:
Moderna, Inc (MRNA) News:
Below you will find a list of latest news for Moderna, Inc (MRNA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Moderna, Inc (MRNA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest MRNA Trades:
Moderna, Inc (MRNA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-30 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-29 | 8-K (Current report) | |
| 2020-10-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-16 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-13 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-13 | 4 (Statement of changes in beneficial ownership of securities) | |
Moderna, Inc (MRNA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Moderna, Inc (MRNA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1001%
Institutional Ownership: 5206%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-05 | Stephane Bancel | Chief Executive Officer | Sell | 10,000.00 | 71.09 | 710,900.00 | 7,684,880.00 | |
| 2020-11-04 | Stephane Bancel | Chief Executive Officer | Sell | 9,000.00 | 68.97 | 620,730.00 | 6,594,868.00 | |
| 2020-11-03 | Stephen Hoge | President | Sell | 10,000.00 | 66.75 | 667,500.00 | 1,754,597.00 | |
| 2020-11-03 | Stephen Hoge | President | Buy | 10,000.00 | 0.99 | 9,900.00 | 1,764,597.00 | |
| 2020-11-02 | Tal Zvi Zaks | Chief Medical Officer | Sell | 1,100.00 | 67.88 | 74,668.00 | 0.00 | |
| 2020-11-02 | Tal Zvi Zaks | Chief Medical Officer | Sell | 13,900.00 | 67.11 | 932,829.00 | 1,100.00 | |
| 2020-11-02 | Tal Zvi Zaks | Chief Medical Officer | Buy | 10,000.00 | 19.15 | 191,500.00 | 15,000.00 | |
| 2020-11-02 | Stephen Hoge | President | Sell | 10,000.00 | 68.02 | 680,200.00 | 1,754,597.00 | |
| 2020-11-02 | Stephen Hoge | President | Buy | 10,000.00 | 0.99 | 9,900.00 | 1,764,597.00 | |
| 2020-11-02 | Tal Zvi Zaks | Chief Medical Officer | Buy | 5,000.00 | 12.21 | 61,050.00 | 5,000.00 | |
| 2020-11-02 | Stephane Bancel | Chief Executive Officer | Sell | 8,893.00 | 68.02 | 604,901.86 | 9,077,048.00 | |
| 2020-10-30 | Stephane Bancel | Chief Executive Officer | Sell | 1,100.00 | 70.69 | 77,759.00 | 331,396.00 | |
| 2020-10-30 | Stephane Bancel | Chief Executive Officer | Sell | 2,740.00 | 69.50 | 190,430.00 | 332,496.00 | |
| 2020-10-30 | Stephane Bancel | Chief Executive Officer | Sell | 1,500.00 | 68.24 | 102,360.00 | 335,236.00 | |
| 2020-10-30 | Stephane Bancel | Chief Executive Officer | Sell | 5,706.00 | 67.40 | 384,584.40 | 336,736.00 | |
| 2020-10-29 | Stephane Bancel | Chief Executive Officer | Sell | 10,000.00 | 68.39 | 683,900.00 | 7,694,880.00 | |
| 2020-10-28 | Stephane Bancel | Chief Executive Officer | Sell | 9,000.00 | 68.75 | 618,750.00 | 6,604,868.00 | |
| 2020-10-26 | Tal Zvi Zaks | Chief Medical Officer | Sell | 2,100.00 | 70.99 | 149,079.00 | 0.00 | |
| 2020-10-26 | Tal Zvi Zaks | Chief Medical Officer | Buy | 10,000.00 | 19.15 | 191,500.00 | 15,000.00 | |
| 2020-10-26 | Stephen Hoge | President | Sell | 300.00 | 71.13 | 21,339.00 | 1,754,597.00 | |